Putnam’s Centers of Excellence allow us to dig deep, challenge convention, and take you further with strategies underpinned by technical expertise in cutting-edge topics.
We provide world-class thought partnership and solutions that enhance the business impact of medical and scientific affairs.
Transform life sciences with AI-driven data strategies for impactful insights across the product lifecycle.
Learn about our data strategy and analytics services for pharmaceutical companies in the life science industry.
Mobile navigation menu modal
Explore our latest insights and perspectives in these life science resources, news articles, and events.
Key insights from ISPOR Europe 2025 on evolving HEOR, RWE, AI-driven evidence, patient-centered outcomes, and the future of market access.
As obesity care surges past $100B, biopharma, payers, and providers face a new era of opportunity.
At ESMO 2025, science set the pace, but Precision Medical Affairs defined the path, turning complexity into clarity and innovation into impact.
Predictive insight meets human intelligence, reshaping EU HTA readiness through smarter, data-driven evidence planning.
Equity in HTA is evolving. Explore current guidelines, future trends, and how Putnam advances equity methods in health assessments.
Discover how real-world external control arms (RW-ECAs) provide robust comparative evidence for HTA submissions when RCTs are impractical or unethical
In pharma commercialization, AI and analogs set the stage, but human insight drives strategies that break precedent and win markets
Explore how AI is reshaping Medical Affairs, driving precision, enhancing patient outcomes, and unlocking new opportunities for biopharma in 2025
CAR-T innovation in solid tumors shows mixed results at ASCO® 2025, progress seen, but safety, delivery & durability challenges remain.
Explore how MAPS EMEA 2025 redefined Medical Affairs - patient-centricity, AI, evidence generation & launch excellence take center stage
Explore the latest executive order on drug pricing, focusing on IRA pill penalty reform, its implications for Medicare savings, and pharma market..
Looking to get in touch with an expert or team member?
Tell us how we can help.
